tarlatamab news

All news on tarlatamab (also known as IMDELLTRA): plants, production capacities, investments and involved companies.

8 September 2026

Amgen: IMDELLTRA plus Imfinzi improves overall survival in first‑line maintenance ES‑SCLC

Tarlatamab (IMDELLTRA) plus durvalumab showed statistically significant OS, PFS and ORR benefits versus durvalumab alone in Phase 3 DeLLphi‑305 for first‑line maintenance ES‑SCLC.

Who will be producing tarlatamab in the future?

Find out with chemXplore Alpha

Learn more